Navigation Links
Nastech Announces Third Quarter 2007 Financial Results
Date:10/29/2007

BOTHELL, Wash., Oct. 29 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) today reported financial results for the three- and nine-month periods ended September 30, 2007.

Revenue for the quarter ended September 30, 2007 was $1.9 million, compared to $5.5 million for the quarter ended September 30, 2006. The 2006 period included revenue of $4.8 million related to our Parathyroid Hormone (PTH1-34) nasal spray collaboration with Procter & Gamble Pharmaceuticals, Inc. ("P&G"). Revenue for the nine months ended September 30, 2007 was $11.7 million, compared to $23.7 million for the nine months ended September 30, 2006. The 2007 period included receipt and recognition of a $2.0 million payment from QOL Medical LLC related to the June 2007 issuance of a patent by the U.S. Patent and Trademark Office for Nascobal(R) nasal spray, and revenue recognized related to our collaboration agreement with P&G, revenue from our other agreements including Novo Nordisk A/S and Amylin Pharmaceuticals, Inc. and approximately $0.2 million in Nascobal(R) product revenue. The prior year nine month period included recognition of approximately $3.7 million in previously deferred revenue from Merck & Co., Inc. related to our PYY(3-36) obesity program, a $7.0 million milestone payment and reimbursement revenue related to our development agreement with P&G, revenue from other agreements and approximately $0.6 million in Nascobal(R) product revenue.

Net loss for the current quarter was $16.5 million, or $0.66 per share, as compared to a net loss of $7.8 million, or $0.36 per share for the prior year period. The net loss for the nine months ended September 30, 2007 was $40.4 million or $1.62 per share, as compare
'/>"/>

SOURCE Nastech Pharmaceutical Company Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... and THOUSAND OAKS, Calif., Dec. 14 ... Amgen Inc.(Nasdaq: AMGN ) today announced that ... worldwide rights to Array,s small-molecule glucokinase activator program, ... 1 clinical trial in patients with Type 2 ... the agreement, Array will receive an upfront payment ...
(Date:12/14/2009)... NATICK, Mass., Dec. 14 Boston Scientific Corporation ... of a public offering of $2 billion aggregate principal ... registration statement. The public offering consists of $850 ... million of 6.00 percent notes due January 2020 and ... Boston Scientific plans to use the net proceeds ...
(Date:12/14/2009)... - Results From a Survey Conducted by ... Major Industrialized Countries , , - A ... impacts their enjoyment of the ... arthritis find shopping for gifts, ... difficult to do, ...
(Date:12/11/2009)... CHESTNUT HILL, MA (12/11/2009) Boston College researchers have ... for the first time and successfully harvested the elusive ... to improved solar power efficiency, the authors report in ... . , When light is captured in solar cells, ... states. But in order to snare these charges, the ...
Breaking Biology Technology:Array BioPharma and Amgen Partner in Type 2 Diabetes 2Array BioPharma and Amgen Partner in Type 2 Diabetes 3Array BioPharma and Amgen Partner in Type 2 Diabetes 4Array BioPharma and Amgen Partner in Type 2 Diabetes 5Array BioPharma and Amgen Partner in Type 2 Diabetes 6Array BioPharma and Amgen Partner in Type 2 Diabetes 7Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 2Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 2Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 4Elusive 'hot' electrons captured in ultra-thin solar cells 2
... 7 GlaxoSmithKline plc (LSE/NYSE: GSK ) ... by its wholly-owned subsidiary Gemstone Acquisition Corporation for shares ... GNLB ). The tender offer expired at 12:00 ... 2009.The depositary for the tender offer has advised GSK ...
... Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical ... Company will present,data from two ongoing Phase 2 clinical ... Oncology (ASCO) Symposia. , In ... Phase 2 trial,of picoplatin in patients with metastatic colorectal ...
... Jan. 7 Dr. Ryan Burnette, Director of Alliance ... 19, 2009 through January 23, 2009. Dr. Burnette ... for high-containment biomedical labs as a lynchpin to an ... excited to visit Singapore, a progressive country that has ...
Other Biology Technology:GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc. 2Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers 2Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers 3Alliance Biosciences Announces Trade Mission to Singapore with Speaker Presentation at International Lab Design Seminar 2Alliance Biosciences Announces Trade Mission to Singapore with Speaker Presentation at International Lab Design Seminar 3
(Date:12/14/2009)... is in preventing some of the stresses of open surgery ... flow and organ dysfunction. Laparoscopy is a type of surgery ... , By adding another gas to the carbon dioxide ... Duke University Medical Center have found they can preserve more ... ethyl nitrite (ENO) helped to open blood vessels and keep ...
(Date:12/13/2009)... discovered five genetic variants that are associated with the ... international consortium of 96 scientists from 63 centres in ... basis of lung diseases. , The new findings provide ... Obstructive Pulmonary Disease (COPD) and asthma. In the past ... the molecular pathways that affect the health of the ...
(Date:12/11/2009)... COLLINS, COWild Malus orientalis species of wild apples ... native to the Middle East and Central Asia. A ... M. orientalis varieties from Georgia and Armenia with ... the large population and establishes a core collection that ... the breeding and research communities. , To identify and ...
Breaking Biology News(10 mins):Gas improves blood flow and organ status during minimally invasive surgery 2New genes for lung disease discovered 2Understanding apples' ancestors 2AUDIO from Medialink and Majestic Drug Company 3A When the Tooth Hurts 60261 1Shu Tung Li Founder and CEO of Collagen Matrix Inc Honored as 2009 New Jersey Executive of the Year Finalist and Company Named One of Fifty Fastest 60257 1Shu Tung Li Founder and CEO of Collagen Matrix Inc Honored as 2009 New Jersey Executive of the Year Finalist and Company Named One of Fifty Fastest 60257 2Jedi Mind Inc in Excellent Financial Shape to Expand Business 60253 1Jedi Mind Inc in Excellent Financial Shape to Expand Business 60253 2
... white oak were once widespread in the Pacific Northwests ... suppression, conifer and invasive plant encroachment, and land use ... as 99 percent of the oak communities historically present ... technical report titled "Evaluation of Landscape Alternatives for Managing ...
... and technological advances, which tend to take their place ... of public debate and regulatory attention, due partly to ... , In this second BBVA Foundation international study ... the sample has been enlarged from nine to twelve ...
... Its a paradox that has confounded evolutionary biologists since ... Since parasites depend on their hosts for survival, why do ... Emory University study of monarch butterflies and the microscopic parasites ... strike a middle ground between the benefits gained by reproducing ...
Other Biology News:BBVA Foundation international study on attitudes to stem cell research 2BBVA Foundation international study on attitudes to stem cell research 3BBVA Foundation international study on attitudes to stem cell research 4BBVA Foundation international study on attitudes to stem cell research 5BBVA Foundation international study on attitudes to stem cell research 6Monarch butterflies help explain why parasites harm hosts 2Monarch butterflies help explain why parasites harm hosts 3
... results - with a modular approach to ... The ChemStation Plus NDS family provides modular ... and data management, giving you the flexibility ... labs needs now and that can grow ...
... Control at its Best: DASGIPs Process ... Online Changes & comprehensive documentation for ... parameters auch as pH, dissolved oxygen, ... and changeable online. Profiles, e.g. constant ...
... designed for immunological studies, vaccine development, ... flexible and powerful Paraflo microfluidic on-chip ... as part of our comprehensive Epitope ... Probe Content Probe content is ...
... designed to meet your needs. Two probe ... per array (2 arrays/1" x 3" glass ... array/slide). Features ... extended length delivers higher sensitivity compared to ...
Biology Products: